Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TONIC-3: Novel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer
2023-507875-23-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab, tiragolumab and ipilimumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Progression-free survival rate at 12 weeks (RECIST 1.1) and Safety and immune-related toxicity (CTCAE v5.0). Planned start Jan 2024; status: authorised.
02
Drugs
atezolizumabtiragolumabipilimumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-507875-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507875-23-00.